Nevertheless, there is evidence that CTLA4-Ig are affecting macrophages, which was already shown for abatacept, a first-generation CTLA4-Ig that is frequently used in the treatment of patients with rheumatoid arthritis. This evidence concerns the gene CTLA4 and rheumatoid arthritis.